STOCK TITAN

Incyte Genomics (INCY) Stock News, May-Aug 2022

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Summary

Incyte announced multiple abstracts from its dermatology portfolio will be presented at the EADV Congress from September 7-10, 2022. Highlights include data on the FDA-approved ruxolitinib cream for vitiligo and the oral JAK1 inhibitor povorcitinib, advancing into Phase 3 for hidradenitis suppurativa. Key presentations include efficacy and safety analyses of ruxolitinib cream and insights from the VALIANT study on vitiligo's mental health impacts. The MAA for ruxolitinib cream is under review by the EMA, reinforcing Incyte’s focus on innovative dermatological treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
Rhea-AI Summary

Incyte will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 12:30 p.m. EDT in New York. The presentation will be available via live webcast on Investor.Incyte.com and will be accessible for replay for 30 days. Based in Wilmington, Delaware, Incyte is a global biopharmaceutical company dedicated to addressing serious unmet medical needs through innovative therapeutics. For more information, visit Incyte.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences
-
Rhea-AI Summary

Incyte reported its Q2 2022 financial results, showing a significant 29% increase in total revenues to $911 million year-over-year. Product revenues of $664 million grew by 15%, with Jakafi leading at $598 million (+13% Y/Y). The company raised its full-year guidance for Jakafi to $2.36 to $2.40 billion. Notable approvals for Opzelura in vitiligo and Olumiant for alopecia areata enhance growth prospects. However, operational costs surged, with SG&A expenses rising 50% due to commercial activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
Rhea-AI Summary

Incyte has announced the FDA approval of Opzelura (ruxolitinib) cream 1.5%, the first and only topical treatment for nonsegmental vitiligo in patients aged 12 and older. Based on Phase 3 TRuE-V clinical trials, approximately 30% of patients achieved significant improvements in facial repigmentation at Week 24, increasing to 50% by Week 52. Opzelura is significantly impactful as it addresses a major unmet medical need, with potential for broad market appeal. An investor conference call is scheduled for July 19, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
-
Rhea-AI Summary

Incyte has scheduled its Q2 2022 financial results conference call for August 2, 2022, at 8:00 a.m. ET. The press release detailing these results will be available earlier on the same day at 7:00 a.m. ET. Investors can dial in using the domestic number 877-407-3042 or international number 201-389-0864, with the conference ID 13731520. A replay will be available for thirty days. Interested parties can also access the live webcast with slides via Incyte's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
-
Rhea-AI Summary

Eli Lilly and Incyte announced that the FDA has approved OLUMIANT (baricitinib) as the first systemic treatment for adults with severe alopecia areata. Available in 1 mg, 2 mg, and 4 mg doses, OLUMIANT has shown promising results in clinical trials, with 32-35% of patients achieving over 80% scalp coverage. The approval follows the BRAVE-AA1 and BRAVE-AA2 trials, involving 1,200 patients. While the treatment offers hope for patients, it comes with serious risks, including infections and cardiovascular events. Manufacturers are also working on patient access programs to help with costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
Rhea-AI Summary

Pfizer, MorphoSys, and Incyte announced a clinical trial collaboration to explore the immunotherapeutic combination of Pfizer's TTI-622 with MorphoSys's Monjuvi and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation. Pfizer will lead a multicenter Phase 1b/2 study, which is set to take place in North America, Europe, and Asia-Pacific. The initiative addresses significant unmet medical needs in DLBCL treatment and follows promising preclinical data regarding TTI-622's potential efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
-
Rhea-AI Summary

Incyte announced that multiple abstracts from its oncology portfolio will be presented at the European Hematology Association Congress 2022, taking place from June 9-17 in Vienna and virtually. Key studies include long-term efficacy results of Parsaclisib for autoimmune hemolytic anemia, and evaluations of Ruxolitinib for various hematological conditions. All ePoster presentations will be available on-demand beginning June 10. Incyte remains committed to addressing serious unmet medical needs, particularly in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary

Incyte (Nasdaq:INCY) will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on June 14, 2022, at 8:00 a.m. PDT / 11:00 a.m. EDT in Rancho Palos Verdes. The presentation will be available via a live webcast on the company's investor website, with a replay accessible for 30 days. Incyte is a Wilmington, Delaware-based biopharmaceutical company committed to developing proprietary therapeutics to address serious unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
conferences
Rhea-AI Summary

Eli Lilly and Incyte announced a positive opinion from the European Medicines Agency's CHMP for OLUMIANT (baricitinib) to treat adults with severe alopecia areata. This opinion signals the potential for the first oral treatment and JAK inhibitor for severe alopecia areata in the EU, pending final approval from the European Commission, expected in the next 1-2 months. The judgment is based on the successful Phase 3 BRAVE-AA1 and BRAVE-AA2 trials, involving 1,200 patients, showing significant efficacy compared to placebo. The FDA has granted priority review for the same indication in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.